Valerio Gristina

Valerio Gristina

Auto-generated profile, based on publicly available information

Valerio Gristina

Aoup Paolo Giaccone, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo/IT

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
RLRossella De Luca
Rossella De Luca
LBLivio Blasi
Livio Blasi
MAMassimiliano Alù
Massimiliano Alù
VGValerio Gristina
Valerio Gristina
GCGiuseppe Cicero
Giuseppe Cicero
Purpose: Pancreatic carcinoma is the neoplasia with the major mortality, and main standard treatments in this cancer increase survival but do not lead to complete recovery of the patient. The aim of this study was to evaluate the efficacy of Abraxane® (nab-paclitaxel) in Italian patients with metastatic pancreatic cancer (MPC). Patients and methods: We conducted a retrospective analysis of 80 patients. Overall survival (OS) was the primary end point for evaluating the efficacy of nab-paclitaxel in combination with gemcitabine treatment, while carbohydrate antigen 19-9 (CA 19-9) reduction, safety, progression-free survival (PFS), overall response rate and reduction in pain were secondary end points. Results: The median OS was 8 months, and the median PFS was 5 months. A considerable difference in CA 19-9 before and after treatment was observed. Descriptive and correlation analyses were done to examine the relationship between CA 19-9 response and OS. Linear regression analysis between OS and CA 19-9 response revealed that CA 19-9 is an important predictor of OS, showing a positive correlation. Conclusion: Nab-paclitaxel is a well-tolerated and effective treatment for patients affected by MPC. The drug showed an improved tolerability profile, significant pain relief and an increase in survival rate.

3 January 2024 in Epigenomics
Verified
Journal Article
Closed access
VGValerio Gristina
Valerio Gristina
UMUmberto Malapelle
Umberto Malapelle

18 September 2017 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
NBN. Barraco
N. Barraco
LILorena Incorvaia
Lorena Incorvaia
GBGiuseppe Badalamenti
Giuseppe Badalamenti
FPF. Passiglia
F. Passiglia
ALAngela Listi
Angela Listi
Antonio RussoAntonio Russo
Antonio Russo
Background: Long non-coding RNAs (lncRNAs) are emerging as essential regulators of genetic and epigenetic networks. Their deregulation may underlie carcinogenesis suggesting their potential involvement in tumorigenic and metastatic processes, as well as their role as prognostic/predictive biomarkers for clinical use in patients with several solid tumors. Few studies evaluated lncRNAs expression in rare tumors such as Gastrointestinal Stromal Tumors (GISTs). Indeed, the upregulation of HOTAIR has been associated with tumor aggressiveness and metastasis, and poor survival of GIST patients. In order to gain more detailed insight on the molecular role of lncRNAs, we analyzed the expression levels of lncRNAs H19, MALAT1 and HOTAIR in tissue specimens of surgically resected GIST patients to evaluate the potential role of lncRNAs as prognostic biomarkers.

1 March 2021 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
Antonio GalvanoAntonio Galvano
Antonio Galvano
VGV. Gristina
V. Gristina
LIL. Insalaco
L. Insalaco
MMM. La Mantia
M. La Mantia
APA. Perez
A. Perez
ARALESSIA RUSSO
ALESSIA RUSSO

7 October 2021
Verified
Book Chapter
Closed access
PDF file
Fiorella GuadagniFiorella Guadagni
Fiorella Guadagni
SCSofia Cutaia
Sofia Cutaia
GMGiorgio Madonia
Giorgio Madonia
VGValerio Gristina
Valerio Gristina
LILorena Incorvaia
Lorena Incorvaia
PVPaolo VIGNERI
Paolo VIGNERI

1 September 2021 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
VGV. Gristina
V. Gristina
Antonio GalvanoAntonio Galvano
Antonio Galvano
MMMario Mirisola
Mario Mirisola
MMM. La Mantia
M. La Mantia
MGM. Giaconia
M. Giaconia
Viviana BazanViviana Bazan
Viviana Bazan
Breast cancer susceptibility genes 1 and 2 (BRCA 1/2) pathogenic germline variants (gPV) are involved in an increased cumulative risk for cancers (above all breast and ovarian cancers). Overweight/obesity is a well-known systemic condition conferring higher cancer risk too.